Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)

Data from ORIENT-11 show that the addition of sintilimab, an anti-PD-1 antibody, to first-line platinum-based chemotherapy enhances efficacy in patients with locally advanced or metastatic nonsquamous NSCLC. More info

eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.

Interim results of the randomized, open-label, phase III eXalt3 trial showed that ensartinib excelled over crizotinib in patients with locally advanced or metastatic ALK-positive NSCLC who were naïve to ALK-targeted therapy. More info

 

 

The randomized phase III CheckMate 743 trial shows the benefit of a chemotherapy-free regimen in patients with previously untreated disease.  More info